The world's only transdermal nonsteroidal anti-inflammatory drug for cancer pain—ZICTHORU Tapes 75mg

ZICTHORU Tapes 75mg Physical picture

Source: Japan Jiuguang official website

With the progression of cancer, the frequency of cancer pain increases, which will not only cause physical pain, but also have psychological and social effects, thus significantly reducing the quality of life and daily activities of patients. According to Japanese and international pain management guidelines, the drug treatment of cancer pain should be selected according to the degree of pain of patients. Patients should use non opioid analgesics, such as non steroidal anti-inflammatory drugs (NSAIDs) or paracetamol, or opioid analgesics, which should be used alone or in combination according to the condition. Among them, the combination of non steroidal anti-inflammatory drugs and opioid analgesics is also expected to produce additive or synergistic analgesic effects. However, in Japan, among the non opioid analgesics including non steroidal anti-inflammatory drugs, the preparations that can be used for cancer pain are limited to oral and injection drugs.

Diclofenac sodium is a non steroidal anti-inflammatory drug based on phenylacetic acid, which shows analgesic and anti-inflammatory effects by inhibiting cyclooxygenase (COX). Compared with other non steroidal anti-inflammatory drugs, diclofenac sodium has higher COX-2 inhibitory activity, mainly inducing expression in inflammatory sites. In Japan, tablets, sustained-release capsules, suppositories, eye drops, gel, enemas, tapes, patches, lotions and creams have been widely used in various clinical departments.

ジクトルテープ/ ZICTHORUIt is a transdermal preparation of diclofenac sodium and the first transdermal nonsteroidal anti-inflammatory drug used to treat persistent cancer pain in the world. Once a day, it is expected to maintain a stable plasma drug concentration for 24 hours and continuously inhibit cancer pain. The product is expected to be used in cancer pain patients who have nausea, vomiting, dysphagia, gastrointestinal obstruction, etc. related to the treatment of basic diseases or anticancer drugs and are difficult to take oral drugs.

ジクトルテープ/ ZICTHORUIts efficacy and safety were confirmed in two phase III clinical trials (randomized, placebo-controlled, double-blind, controlled trials and open label long-term drug administration studies) for cancer pain patients completed in Japan.
Side effects include itching at the application site (5% or more), erythema at the application site, epigastric pain, elevated ast, ALT and creatinine (all lower than 1-5%). Significant side effects include shock, anaphylaxis, gastrointestinal ulcer with hemorrhagic shock or perforation, gastrointestinal stenosis / obstruction, aplastic anemia, hemolytic anemia, agranulocytosis, thrombocytopenia and toxic epidermal necrolysis, Johnson syndrome, erythema (exfoliative dermatitis), acute kidney disease (interstitial nephritis, renal papillary necrolysis, etc.), nephrotic syndrome It may lead to asthma attack (aspirin asthma), interstitial pneumonia, congestive heart failure, myocardial infarction, aseptic epidermal nephritis, severe liver dysfunction, acute encephalopathy, rhabdomyolysis, cerebrovascular disease, etc.

Please pay attention to the following points when using drugs:

• Since the whole-body exposure when using 3 patches of this product is at the same level as the normal dose of oral drugs with the same components, the number of patches used per day cannot exceed 3.

• The indications of this product are different from other previously marketed patches containing diclofenac.

• When this product is administered, it should not be used in combination with other anti-inflammatory and analgesic drugs. If it cannot be avoided, it should be used as little as possible, and close attention should be paid to the patient's condition.

[figure 1, product DA]

Source: Social Network

"Attached figure 2, science and Technology Commission site"

Source: Social Network

END